Lupus-prone New Zealand Black/New Zealand white F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells

Lupus

Volumn 19, Issue 3, 2010, Pages 288-299

  Thacker, S G ^a   Duquaine, D ^a   Park, J ^a   Kaplan, M J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Endothelial progenitor cells; Endothelium; Interferon alpha; Systemic lupus erythematosus

Indexed keywords

ACETYLCHOLINE; ALPHA INTERFERON; NITROPRUSSIDE SODIUM;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SMOOTH MUSCLE; STEM CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; THORACIC AORTA; VASODILATATION; VASOMOTOR REFLEX;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; APOPTOSIS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; FEMALE; INTERFERON TYPE I; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NZB; NITROPRUSSIDE; PHENOTYPE; STEM CELLS; VASODILATOR AGENTS;

EID: 77749251784     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309353773     Document Type: Article

References (53)

1. Manzi S., Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997 ; 145: 408-415.
2. Aranow C., Ginzler EM Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000 ; 9: 166-169.
3. Esdaile JM, Abrahamowicz M., Grodzicky T., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001 ; 44: 2331-2337.
4. Rajagopalan S., Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004 ; 103: 3677-3683.
5. Roman MJ, Devereux RB, Schwartz JE, et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005 ; 46: 194-199.
6. Bruce IN, Gladman DD, Ibanez D., Urowitz MB Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. J Rheumatol 2003 ; 30: 288-291.
7. Anderson TJ, Gerhard MD, Meredith IT, et al. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995 ; 75: 71B - 74B.
8. Denny MF, Thacker S., Mehta H., et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007 ; 110: 2907-2915.
9. Lee PY, Li Y., Richards HB, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007 ; 56: 3759-3769.
10. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005 ; 35: 999-1007. (Pubitemid 41262334)
11. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001 ; 89: E1 - E7.
12. Grisar J., Aletaha D., Steiner CW, et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005 ; 111: 204-211.
13. Heiss C., Amabile N., Lee AC, et al. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production. J Am College Cardiol 2008 ; 51: 1760-1771.
14. Hoenig MR, Bianchi C., Rosenzweig A., Sellke FW Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Current Mol Med 2008 ; 8: 754-767.
15. Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006 ; 25: 383-392. (Pubitemid 44354221)
16. Hsueh W., Abel ED, Breslow JL, et al. Recipes for creating animal models of diabetic cardiovascular disease. Circulation Res 2007 ; 100: 1415-1427.
17. Feng X., Li H., Rumbin AA, et al. ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. J Lipid Res 2007 ; 48: 794-805.
18. Ma Z., Choudhury A., Kang SA, Monestier M., Cohen PL, Eisenberg RA Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clin Immunol 2008 ; 127: 168-175.
19. Aprahamian T., Rifkin I., Bonegio R., et al. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med 2004 ; 199: 1121-1131.
20. Stanic AK, Stein CM, Morgan AC, et al. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci U S A 2006 ; 103: 7018-7023.
21. Ryan MJ, McLemore GR Jr. Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 2007 ; 292: R736 - R742.
22. Lian ZX, Kikuchi K., Yang GX, Ansari AA, Ikehara S., Gershwin ME Expansion of bone marrow IFN-alpha-producing dendritic cells in New Zealand Black (NZB) mice: high level expression of TLR9 and secretion of IFN-alpha in NZB bone marrow. J Immunol 2004 ; 173: 5283-5289.
23. Mathian A., Weinberg A., Gallegos M., Banchereau J., Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005 ; 174: 2499-2506.
24. Nacionales DC, Kelly-Scumpia KM, Lee PY, et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheumatism 2007 ; 56: 3770-3783.
25. Barrat FJ, Meeker T., Chan JH, Guiducci C., Coffman RL Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007 ; 3: 3582-3586.
26. Lu Q., Shen N., Li XM, Chen SL Genomic view of IFN-alpha response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immunity 2007 ; 8: 590-603.
27. Ponticelli C., Zucchelli P., Passerini P., et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. New Engl J Med 1989 ; 320: 8-13.
28. Schwarting A., Paul K., Tschirner S., et al. Interferon-{beta}: A therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol 2005 ; 16: 3264-3272.
29. Hron JD, Peng SL Type I IFN protects against murine lupus. J Immunol 2004 ; 173: 2134-2142.
30. Park JL, Loberg RD, Duquaine D., et al. GLUT4 facilitative glucose transporter specifically and differentially contributes to agonist-induced vascular reactivity in mouse aorta. Arterioscler Thrombosis Vasc Biol 2005 ; 25: 1596-1602.
31. Park JL, Heilig CW, Brosius FC III. GLUT1-deficient mice exhibit impaired endothelium-dependent vascular relaxation. Eur J Pharmacol 2004 ; 496: 213-214.
32. Chakroborty D., Chowdhury UR, Sarkar C., Baral R., Dasgupta PS, Basu S. Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J Clin Invest 2008 ; 118: 1380-1389.
33. Silverman MD, Haas CS, Rad AM, Arbab AS, Koch AE The role of vascular cell adhesion molecule 1/ very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheumatism 2007 ; 56: 1817-1826.
34. Livak KJ, Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001 ; 25: 402-408.
35. Westerweel PE, Luijten Rkmac, Hoefer IE, Koomans HA, Derksen Rhwm, Verhaar MC Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis 2007 ; 66: 865-870.
36. Grisar J., Steiner CW, Bonelli M., et al. Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology 2008 ; 47: 1476-1483.
37. Zhu S., Liu X., Li Y., Goldschmidt-Clermont PJ, Dong C. Aging in the atherosclerosis milieu may accelerate the consumption of bone marrow endothelial progenitor cells. Arterioscler Thrombosis Vasc Biol 2007 ; 27: 113-119.
38. Hill JM, Zalos G., Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. New Engl J Med 2003 ; 348: 593-600.
39. Werner N., Junk S., Laufs U., et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circulation Res 2003 ; 93: e17 - e24.
40. Halcox JP, Schenke WH, Zalos G., et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002 ; 106: 653-658.
41. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 ; 340: 1111-1115.
42. London GM, Guerin AP, Marchais SJ, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996 ; 50: 600-608.
43. London GM, Marchais SJ, Guerin AP, Metivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005 ; 14: 525-531.
44. Lartaud-Idjouadiene I., Lompre A-M., Kieffer P., Colas T., Atkinson J. Cardiac consequences of prolonged exposure to an isolated increase in aortic stiffness. Hypertension 1999 ; 34: 63-69.
45. Herbrig K., Pistrosch F., Foerster S., Gross P. Endothelial progenitor cells in chronic renal insufficiency. Kidney Blood Pressure Res 2006 ; 29: 24-31.
46. Oates JC, Gilkeson GS Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice. J Investig Med 2004 ; 52: 62-71.
47. Licht R., van Bruggen MC, Oppers-Walgreen B., Rijke TP, Berden JH Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration. Arthritis Rheumatism 2001 ; 44: 1320-1330.
48. Benihoud K., Bonardelle D., Bobe P., Kiger N. MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways. Eur J Immunol 1997 ; 27: 415-420.
49. Njoku C., Self SE, Ruiz P., Hofbauer AF, Gilkeson GS, Oates JC Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. J Investig Med 2008 ; 56: 911-919.
50. Okon EB, Szado T., Laher I., McManus B., van Breemen C. Augmented contractile response of vascular smooth muscle in a diabetic mouse model. J Vasc Res 2003 ; 40: 520-530.
51. Broxmeyer HE, Lu L., Platzer E., Feit C., Juliano L., Rubin BY Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983 ; 131: 1300-1305.
52. Papadaki HA, Boumpas DT, Gibson FM, et al. Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br J Haematol 2001 ; 115: 167-174.
53. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L., Crow MK, Niewold TB Cutting edge: Autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009 ; 182: 34-38.